Psychotic disorders are severe mental disorders characterized by disturbances in thinking, perception, emotion, and behavior. Psychosis involves a loss of contact with reality, manifesting as hallucinations, delusions, disorganized thinking, and negative symptoms.
Overview of Psychotic Disorders
| Disorder | Core Feature | Duration | Mood Symptoms |
|---|---|---|---|
| Schizophrenia | Two or more psychotic symptoms (positive, negative, disorganized) | 6+ months | May be present but not predominant |
| Schizoaffective disorder | Mood episode (depressive or manic) + psychotic symptoms | 2+ weeks of psychosis without mood episode | Required |
| Delusional disorder | One or more delusions for 1+ month | 1+ month | Not prominent |
| Brief psychotic disorder | Sudden onset of psychotic symptoms | 1 day to 1 month | May be present |
| Schizophreniform disorder | Symptoms of schizophrenia | 1-6 months | May be present |
| Substance/medication-induced psychotic disorder | Psychosis due to substance | Duration of substance effect | Variable |
Schizophrenia
Schizophrenia is a chronic, severe mental disorder affecting approximately 1% of the population worldwide. It is characterized by positive symptoms, negative symptoms, and cognitive impairment.
Epidemiology
| Metric | Value |
|---|---|
| Lifetime prevalence | ~0.3-1.0% |
| Annual incidence | ~15 per 100,000 |
| Male:female ratio | 1.4:1 |
| Mean age of onset (males) | 18-25 years |
| Mean age of onset (females) | 25-35 years |
| Lifetime suicide risk | ~5-10% |
| Premature mortality | 10-25 years reduced life expectancy |
DSM-5 Diagnostic Criteria
| Criterion | Description |
|---|---|
| A. Characteristic symptoms | Two or more of following (at least one must be 1, 2, or 3): (1) Delusions, (2) Hallucinations, (3) Disorganized speech, (4) Grossly disorganized or catatonic behavior, (5) Negative symptoms |
| B. Social/occupational dysfunction | Significant impairment in work, interpersonal relations, or self-care |
| C. Duration | Continuous signs for at least 6 months (includes prodromal, active, residual phases) |
| D. Exclusion (schizoaffective/mood) | Schizoaffective and mood disorders ruled out |
| E. Exclusion (substance/medical) | Not attributable to substance use or medical condition |
| F. Relationship to ASD | If history of autism or communication disorder, prominent delusions/hallucinations required for schizophrenia diagnosis |
Symptom Domains
Positive symptoms (psychotic):
| Symptom | Description | Subtypes |
|---|---|---|
| Delusions | Fixed false beliefs maintained despite evidence to contrary | Persecutory, referential, grandiose, erotomanic, nihilistic, somatic, bizarre |
| Hallucinations | Perception-like experiences without external stimulus | Auditory (most common), visual, tactile, olfactory, gustatory |
| Disorganized thinking/speech | Derailment, tangentiality, incoherence, word salad | Formal thought disorder |
| Disorganized behavior | Unpredictable agitation, childlike silliness, social disinhibition | Catatonia (motor immobility, stupor, excitement, posturing) |
Negative symptoms:
| Symptom | Description |
|---|---|
| Affective flattening/blunted affect | Reduced emotional expression, diminished facial expression |
| Alogia | Poverty of speech, reduced verbal output |
| Avolition | Reduced initiation and persistence in goal-directed activities |
| Anhedonia | Reduced ability to experience pleasure |
| Asociality | Reduced social interest and engagement |
Cognitive symptoms:
| Domain | Description | Impact |
|---|---|---|
| Attention | Sustained and selective attention deficits | Difficulty following conversations, tasks |
| Working memory | Holding and manipulating information | Impaired planning, follow-through |
| Executive function | Problem-solving, cognitive flexibility | Difficulty adapting to new situations |
| Processing speed | Slowed cognitive processing | Takes longer to complete tasks |
| Social cognition | Emotion recognition, theory of mind | Difficulty reading social cues |
| Verbal learning | Word list learning, recall | Academic and work difficulties |
Neurobiology
Dopamine hypothesis:
- Mesolimbic hyperactivity → positive symptoms
- Mesocortical hypoactivity → negative and cognitive symptoms
- Dopamine D2 receptor blockade correlates with antipsychotic efficacy
Glutamate hypothesis:
- NMDA receptor hypofunction → altered dopamine activity
- NMDA antagonists (PCP, ketamine) produce schizophrenia-like symptoms
Brain structure:
| Finding | Prevalence | Clinical Significance |
|---|---|---|
| Ventricular enlargement | ~80% | Associated with cognitive impairment, negative symptoms |
| Reduced gray matter volume | Progressive in early course | Prefrontal, temporal, thalamic regions |
| Reduced hippocampal volume | ~5-10% reduction | Memory deficits |
| Cortical thinning | Progressive | Related to cognitive decline |
| Reduced total brain volume | ~2-5% reduction | Present at onset |
Connectivity:
- Aberrant functional connectivity (default mode, salience, central executive networks)
- Reduced long-range connections, increased local connections
Genetics:
- Heritability: ~70-85%
- Risk with affected first-degree relative: ~10%
- Risk with monozygotic twin: ~40-50%
- Polygenic: Hundreds of risk variants, each of small effect
- Largest GWAS association: MHC region (immune function)
Course and Phases
Premorbid phase:
- Mild cognitive deficits, motor abnormalities, social difficulties
- Usually childhood/adolescence
Prodromal phase (weeks to years):
- Attenuated psychotic symptoms
- Functional decline
- Withdrawal, deterioration of functioning
- About 20-40% transition to psychosis
Active phase (variable):
- Full positive symptoms
- Acute psychosis
- Requires treatment
Residual phase:
- Reduced positive symptoms
- Negative symptoms, cognitive impairment persist
- Chronic disability may remain
Course specifiers:
- First episode, acute
- Multiple episodes, acute
- Continuous
- Full remission, partial remission
Prognosis
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Onset | Acute, later age | Insidious, early age |
| Premorbid functioning | Good social/occupational | Poor social/occupational |
| Predominant symptoms | Positive | Negative, cognitive |
| Treatment response | Good response | Treatment-resistant |
| Course | Episodic with full inter-episode recovery | Continuous, progressive |
| Family history | Negative | Positive |
| Support system | Strong | Weak or absent |
Treatment-resistant schizophrenia:
- ~20-30% of individuals do not respond adequately to standard antipsychotics
- Clozapine is the gold standard for treatment resistance
- Defined as poor response to at least two adequate trials of different antipsychotics
Schizoaffective Disorder
Schizoaffective disorder is characterized by an uninterrupted period of illness during which there is a major mood episode (depressive or manic) concurrent with psychotic symptoms, and psychotic symptoms must occur for at least two weeks in the absence of a mood episode.
DSM-5 Criteria
| Criterion | Description |
|---|---|
| A. Mood episode + psychosis | Uninterrupted period of illness with concurrent psychotic symptoms and major mood episode |
| B. Psychosis without mood | Delusions or hallucinations for 2+ weeks in the absence of a major mood episode |
| C. Mood episode meets duration | Major mood episode present for majority of total duration of illness |
| D. Exclusion | Not attributable to substance use or medical condition |
Specifiers:
- Bipolar type: Includes manic episodes
- Depressive type: Only major depressive episodes
Schizoaffective vs. Schizophrenia vs. Mood Disorder
| Feature | Schizophrenia | Schizoaffective (Bipolar) | Schizoaffective (Depressive) | Bipolar with Psychosis |
|---|---|---|---|---|
| Psychosis without mood | Yes | Yes | Yes | No |
| Mania | No | Yes | No | Yes |
| Depression | Common but not dominant | Common | Yes | Common |
| Course | Chronic | Episodic with chronic elements | Episodic with chronic elements | Episodic |
| Treatment | Antipsychotic-focused | Mood stabilizer + antipsychotic | Antidepressant + antipsychotic | Mood stabilizer + antipsychotic |
Delusional Disorder
Delusional disorder is characterized by one or more delusions that persist for at least one month without meeting full criteria for schizophrenia.
DSM-5 Criteria
| Criterion | Description |
|---|---|
| A. Delusions | One or more delusions for 1+ month |
| B. No schizophrenia criteria | Criteria for schizophrenia never met |
| C. Functioning | Apart from delusion impact, functioning not markedly impaired |
| D. Mood episodes | If mood episodes occur, they are brief relative to delusional periods |
| E. Exclusion | Not attributable to substance use or medical condition |
Types:
| Type | Content of Delusion |
|---|---|
| Erotomanic | Another person (usually higher status) is in love with them |
| Grandiose | Having special abilities, fame, or identity |
| Jealous | Partner is unfaithful |
| Persecutory | Being conspired against, followed, poisoned, harassed |
| Somatic | Bodily functions or sensations are abnormal |
| Mixed | More than one type |
| Unspecified | None of the above |
Treatment of Psychotic Disorders
Antipsychotic Medications
First-generation (typical) antipsychotics:
| Medication | Potency | Side Effect Profile |
|---|---|---|
| Haloperidol | High | High EPS, low metabolic |
| Fluphenazine | High | High EPS, low metabolic |
| Chlorpromazine | Low | Low EPS, high sedation, high anticholinergic |
| Perphenazine | Medium | Moderate EPS |
| Trifluoperazine | High | High EPS |
| Thioridazine | Low | High anticholinergic, cardiac (QTc) |
Second-generation (atypical) antipsychotics:
| Medication | EPS Risk | Metabolic Risk | Sedation | Prolactin | Weight Gain |
|---|---|---|---|---|---|
| Clozapine | Very low | High | High | None | Very high |
| Risperidone | Moderate (dose-dependent) | Moderate | Moderate | High | Moderate |
| Olanzapine | Low | Very high | High | Low | Very high |
| Quetiapine | Low | High | High | Low | High |
| Aripiprazole | Low | Low | Low | Low | Low-mod |
| Ziprasidone | Low | Low | Low | Low | Low |
| Lurasidone | Low | Low | Low | Low | Low |
| Paliperidone | Moderate (dose-dependent) | Moderate | Moderate | High | Moderate |
| Asenapine | Low | Low-moderate | Low | Low | Low-moderate |
| Brexpiprazole | Low | Low-moderate | Low | Low | Low-moderate |
| Cariprazine | Low | Low | Low | Low | Low-moderate |
Treatment algorithm:
- Start second-generation antipsychotic (excluding clozapine) at low dose, titrate
- If inadequate response at 4-6 weeks, consider switching to another second-generation agent
- If two adequate trials fail, consider clozapine
- Continue maintenance antipsychotic to prevent relapse
Psychological and Social Interventions
| Intervention | Description | Evidence |
|---|---|---|
| Cognitive-behavioral therapy for psychosis (CBTp) | Challenge delusions, reduce distress from hallucinations, develop coping | Strong for positive symptoms |
| Cognitive remediation therapy | Computerized training to improve cognitive function | Moderate for cognition |
| Social skills training | Teaching interpersonal skills, communication | Moderate for social functioning |
| Family psychoeducation | Educate and support families; reduce expressed emotion | Strong for relapse prevention |
| Supported employment | Individual placement and support (IPS) model | Strong for employment outcomes |
| Assertive community treatment (ACT) | Multidisciplinary team, intensive community-based care | Strong for reducing hospitalization |
| Illness management and recovery | Goal-setting, symptom management, relapse prevention | Moderate for self-management |
| Psychosocial rehabilitation | Structured activities, skills building, community integration | Moderate for functioning |
Coordinated Specialty Care (CSC) for First-Episode Psychosis
CSC is a comprehensive, team-based approach for early psychosis:
| Component | Description |
|---|---|
| Psychotherapy | Individual and family CBTp |
| Medication management | Low-dose antipsychotic, shared decision-making |
| Case management | Care coordination, linkage to services |
| Family support and education | Psychoeducation, support groups |
| Supported employment/education | School/work re-engagement |
| Peer support | Peer specialists with lived experience |
References
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). Arlington, VA: APA.
- Kahn, R. S., et al. (2015). Schizophrenia. Nature Reviews Disease Primers, 1, 15067.
- Howes, O. D., et al. (2015). The dopamine hypothesis of schizophrenia. Schizophrenia Bulletin, 41(3), 549-560.
- Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia. JAMA Psychiatry, 77(8), 820-830.
- Leucht, S., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs. Lancet, 382(9896), 951-962.
- Kane, J. M., & Correll, C. U. (6). The treatment of schizophrenia. Journal of Clinical Psychiatry, 82(2).
- National Institute of Mental Health. (2023). Schizophrenia. NIMH.
- Dixon, L. B., et al. (2018). The evidence base for coordinated specialty care. Schizophrenia Research, 204, 51-57.